Few With Myelodysplastic Syndromes Receive Hypomethylating Agents

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 11, 2025.

via HealthDay

MONDAY, Aug. 11, 2025 -- Few patients with myelodysplastic syndromes (MDS) receive treatment with hypomethylating agents (HMAs), with evidence of age-, sex-, and race-related disparities, according to a study published online Aug. 5 in Blood Neoplasia.

Sudipto Mukherjee, M.D., Ph.D., M.P.H., from the Taussig Cancer Institute at the Cleveland Clinic, and colleagues examined factors associated with patterns of HMA use in patients with MDS in a retrospective cohort study involving 49,514 individuals aged 65 years and older with incident MDS during 2012 to 2013.

The researchers found that 16.1 percent of patients received HMAs. Compared with younger individuals (65 to 74 years), the oldest age cohort (85 years and older) had lower odds of receiving HMAs (adjusted odds ratio, 0.41). Significantly lower odds of receiving HMAs were seen for women and Black patients versus men and White patients (adjusted odds ratios, 0.81 and 0.70, respectively). Factors associated with lower odds of receiving four or more cycles of HMAs included treatment with decitabine, having two to three cytopenias, being nursing home residents, and having high frailty (adjusted odds ratios, 0.70, 0.69, 0.64, and 0.50, respectively).

"Given the absence of newly approved therapies over the last two decades, the most impactful way to improve outcomes in newly diagnosed high-risk MDS requires that we do better with the available therapies," Mukherjee said in a statement. "Making changes with these therapies and how they are given (that is, when to treat and how to treat) is a key intervention that can have a huge impact."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-12 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords